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Abstract
Lassa fever is a neglected tropical disease with a significant impact on the health care system of endemic West
African nations. To date, case reports of Lassa fever have focused on laboratory characterisation of serological,
biochemical and molecular aspects of the disease imported by infected individuals from Western Africa to the
United States, Canada, Europe, Japan and Israel. Our report presents the first comprehensive real time diagnosis
and characterization of a severe, hemorrhagic Lassa fever case in a Sierra Leonean individual admitted to the
Kenema Government Hospital Lassa Fever Ward. Fever, malaise, unresponsiveness to anti-malarial and antibiotic
drugs, followed by worsening symptoms and onset of haemorrhaging prompted medical officials to suspect Lassa
fever. A recombinant Lassa virus protein based diagnostic was employed in diagnosing Lassa fever upon
admission. This patient experienced a severe case of Lassa hemorrhagic fever with dysregulation of overall
homeostasis, significant liver and renal system involvement, the interplay of pro- and anti-inflammatory cytokines
during the course of hospitalization and an eventual successful outcome. These studies provide new insights into
the pathophysiology and management of this viral illness and outline the improved infrastructure, research and
real-time diagnostic capabilities within LASV endemic areas.
Background
Lassa virus (LASV), a member of the Arenaviridae
family, is the etiologic agent of Lassa fever, an acute and
often fatal illness endemic to West Africa. There are an
estimated 300,000 - 500,000 cases of Lassa fever each
year [1-3] with a mortality rate of 15%-20% for hospita-
lized patients, which can become as high as 50% during
epidemics [4,5]. Presently, there is no licensed vaccine
or immunotherapy available for prevention or treatment
of this disease. Although the antiviral drug ribavirin is
somewhat beneficial, it must be administered at an early
stage of infection to successfully alter disease outcome,
thereby limiting its utility [6,7]. Furthermore, there is no
commercially available Lassa fever diagnostic assay,
which hampers early detection and rapid implementa-
tion of existing treatment regimens (e.g. ribavirin
administration). The severity of the disease, its ability to
be transmitted by aerosol droplets and the lack of a vac-
cine or therapeutic drug led to its classification as a
National Institutes of Allergy and Infectious Diseases
(NIAID) Category A pathogen and biosafety level-4
(BSL-4) agent. Several imported Lassa fever cases have
been described since 1973 primarily from foreign
nationals displaying signs of the disease upon returning
to native countries or having been evacuated after falling
ill abroad [8-34]. To date, and despite the often severe
nature of Lassa fever in Western African nations,
resources have not been available to perform compre-
hensive daily analysis of blood samples from suspected
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structure improvements at the Kenema Government
Hospital (KGH) Lassa Fever Laboratory (LFL) by Tulane
University, Department of Defense (DoD) and the Uni-
ted States Army Medical Research Institute of Infectious
Diseases (USAMRIID) since 2005 have allowed for the
implementation of sophisticated diagnostic and research
capabilities at this location. Currently the KGH LFL
diagnoses Lassa fever using ELISA and lateral flow
immunoassay (LFI) platforms to detect viral antigen and
virus-specific IgM and IgG levels in the serum of every
suspected case presented to the LFW. Additionally, the
laboratory can assess 14 serum analytes using a Piccolo
®
blood chemistry analyzer coupled with comprehensive
metabolic panel disks. Flow cytometry powered by a 4-
color Accuri
® C6 cytometer is used to perform immu-
nophenotyping and intracellular and bead-based
secreted cytokine analysis. Together, these diagnostic
assays and instruments enabled the analysis of metabolic
and inflammatory functions in real time utilizing the
sera of individuals discussed in this case report with
concomitant appropriate medical intervention.
The main patient case discussed in this report was
closely monitored for nine days during his hospitaliza-
tion, during which time his condition stabilized; he
began walking with supervision and was nearing the end
of ribavirin treatment. These studies herald a new era in
real time diagnosis and management of Lassa hemorrha-
gic fever in resource poor, endemic areas of Western
Africa. They represent a novel platform toward more
efficient and broader control of the effects of this dis-
ease in the population at large.
Methods
Human Subjects: Suspected LF patients, close contacts,
and healthy volunteers were eligible to participate in
these studies as outlined in Tulane University’sI n s t i t u -
tional Review Board (IRB) protocol for this project,
National Institutes of Health/National Institutes of
Allergy and Infectious Diseases guidelines governing the
use of human subject for research, and Department of
Health and Human Services/National Institutes of
Health/National Institute of Allergy and Infectious Dis-
eases Challenge and Partnership Grant Numbers
AI067188 and AI082119. This project was approved by
the Tulane University IRB. Adult patients in this manu-
script have given written informed consent for the pub-
lication of their case details. Written informed consent
was obtained from the adult guardian of patient G-1180
for publication of this case report.
Normal and positive control sera: Serum from one
Sierra Leonean and two Caucasian American volunteers
were used in these studies as normal controls. A serum
sample collected from a 20-year-old pregnant woman
who succumbed to Lassa fever in the KGH Maternity
Ward on August 29, 2010 was used as a positive con-
trol. A single serum sample was collected from this sub-
ject before expiration, and assigned the coded
designation G-1177.
Detection of Lassa virus antigen and Lassa virus-speci-
fic antibodies: Serum levels of Lassa nucleoprotein (NP)-
specific antigen were first determined using LFI modules
currently under pre-clinical development by Corgenix
Medical Corp., Broomfield, CO, U.S.A., and the Lassa
fever consortium (see acknowledgements). The LFI
modules utilize LASV NP specific murine monoclonal
antibodies in a capture line and gold-conjugated detec-
tion reagent. Downstream of the capture line is an anti-
murine polyclonal control line. Serum samples are
added to a sample well followed by buffer solution to
initiate lateral flow through the reagent pads and across
the capture and control lines. The formation of Lassa
NP antigen immune-complexes by the reagents pro-
duces a red signal due to gold conjugate deposition,
allowing visual interpretation or measurement by reflec-
tance. The red signal can be seen within 3-5 minutes
with full signal development between 15-25 minutes.
The positive Lassa fever diagnosis is then confirmed
with a sensitive antigen-capture ELISA employing either
a murine monoclonal or caprine polyclonal capture anti-
body, followed by a peroxidase-labeled caprine reagent
and tetramethylbenzidine (TMB) substrate. A standard
curve was generated withr e c o m b i n a n tL A S VN Pi n
order to quantify serum levels of virus-associated NP.
IgM and IgG levels to recombinant LASV proteins
(NP alone and NP - glycoprotein 1 (GP1) - glycoprotein
complex (GPC) combination) ELISA: Individual LASV
proteins and combinations optimized for detection of
virus-specific IgM and IgG levels in serum were coated
in stripwell plates, blocked, dried, and packaged with
desiccating packs (Corgenix Medical Corp.). For analy-
sis, sera were diluted 1:100 in a proprietary sample dilu-
tion buffer and incubated in wells for 30 minutes at
room temperature, washed, and incubated with opti-
mized HRP-labeled anti-human IgG or IgM conjugates
for an additional 30 minutes. After washing, detection
was performed with TMB substrate for 10 minutes at
room temperature, stopped with sulphuric acid, and
read at A450 in a BioTek ELISA plate reader.
IgM and IgG endpoint titer determination: Sera were
analyzed in 3-fold serial dilutions, starting at 1:50, in
optimized LASV NP, GP1, GP2, Z protein combination
ELISA, as outlined above. Reciprocal titers were calcu-
lated using mean +3 standard deviation (S.D.) cutoffs
established with similarly diluted normal serum controls.
Piccolo
®: The kinetics of fourteen serum analytes were
analyzed daily using a Piccolo
® blood chemistry analyzer
(Abaxis, Inc., Union City, CA) with Comprehensive
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mined for a male in the age range of the patient using
established clinical guidelines. Blood was collected in
serum vacutainer tubes from patients and control
donors and allowed to coagulate for 20 minutes at room
temperature, followed by centrifugation in a tabletop
centrifuge. The serum fraction was collected for analysis
and aliquots were stored in cryovials at -20°C for future
use.
Flow Cytometry: The kinetics of eleven serum cyto-
kines were analyzed daily using an Accuri
® C6 benchtop
cytometer (Accuri Cytometers Inc., Ann Harbor, MI)
with an eBioscience FlowCytomix Human Th1/Th2 11-
plex Kit (Bender MedSystems GmbH, Vienna, Austria).
Serum aliquots collected and frozen throughout the
monitoring timeline were analyzed concurrently at the
end of the study.
Case presentation
Presentation
Case 1: On September 1, 2010 the KGH LFW was con-
tacted by the medical officer of Gondama Hospital in Bo
district, Sierra Leone, concerning a suspected case of Lassa
hemorrhagic fever. The patient was an eight-year-old male
from Sembehun town, Malegohun chiefdom, Kenema dis-
trict, Sierra Leone who had been first seen at the local
health facility on August 30, 2010 (Figure 1). He presented
to the health facility 2 days after the onset of symptoms
with a history of persistent fever, headache, and profuse
oral, nasal, and rectal bleeding. He was then referred to
the Gondama Hospital where he could receive free medi-
cal care. After two days of treatment with anti-malarial
and antibiotic drugs of unknown type and no improve-
ment, the patient was referred to the KGH LFW as a sus-
pected Lassa case. Upon arrival by ambulance at the KGH
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Figure 1 Map of Sierra Leone and expanded view of Eastern Province, with relevant localities and routes travelled by patients in the
current case report. The Eastern Province of Sierra Leone is shown in the inset map with location of Sembehun, where all suspected Lassa
fever cases in the current report originated, and the three localities where patients travelled to and from: Bo, Kenema, and Hangha. The inbound
routes travelled by each patient are indicated in dotted lines, and outbound ones in solid lines. Three deaths from febrile illness in July were
reported to the Outreach team during a local investigation in Sembehun following admission of G-1180 to KGH LFW. The travel history of a 69
year old female and her daughter from Sembehun to Hangha, and subsequently to Kenema, where she succumbed to a febrile illness without
final diagnosis are highlighted. The 42 year old son of the 69 year old female reportedly succumbed to a similar febrile illness with hemorrhage
on August 7 in Sembehun, without a final diagnosis. G-1180 was first transported to Ghondama clinic in Bo on September 1, after being referred
by the local health post in Sembehun on August 30
th with fever and general malaise. The patient was subsequently transported to KGH LFW on
September 2
nd after Lassa fever was suspected based on clinical presentation.
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Page 3 of 14LFW on September 2, 2010, the patient reported having
multiple symptoms including anorexia, malaise, headache,
nausea, abdominal pain, loose black stools, hematemesis,
dysuria, cough, sore throat and retrosternal pain. He pre-
sented with a body temperature of 38°C, a pulse rate of
140 beats/minute, and a respiration rate of 30 (Figure 2).
On examination, he was in obvious pain and lethargic.
Bleeding from the mouth and nose was noted along with
conjunctival injection, facial edema and hepatomegaly.
During the first 24 hours after his admission to KGH
LFW, he had multiple episodes of grossly bloody stools as
well as hematemesis, hemoptysis and hemeturia. This
patient was assigned the coded designation G-1180 upon
initial diagnosis by NP LFI at KGH LFW, which will be
used henceforth.
Clinical Chemistry
On presentation to KGH LFW, his sodium (Na
+), chlor-
ide (Cl
-), total carbon dioxide (TCO2), albumin (Alb)
and total protein (TP) were all below the normal values
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Figure 2 Vital signs for G-1180 and contacts -A and -B during hospitalization at KGHLFW. Core temperature (°C) [▲], pulse [●], and
respiratory rates (per minute) [◆] were measured at regular intervals, usually every 4 hours at the onset, and every 12 hours at later times,
throughout the hospitalization period for each patient. Data points were plotted individually and the normal ranges for each parameter are
indicated by a line (temperature) or boxes (pulse and respiratory rates). A. Patient G-1180. B. G-1180 contacts -A and B.
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Page 4 of 14for a male his age. The liver function panel revealed an
aspartate aminotransferase (AST), alanine transaminase
(ALT) and alkaline phosphatase (ALP) drastically above
the normal range. Additionally, the blood urea nitrogen
(BUN) and BUN: creatinine (Cre) levels were elevated.
His potassium (K
+), total bilirubin (TBil), corrected cal-
cium (Ca
2+) and Cre levels, on the other hand, all were
within the upper normal range (Figure 3A, additional
file 1 figure S1). His hemoglobin (Hb) levels were low
throughout hospitalization (Figure 3B).
A tt h et i m eo fa d m i s s i o nt oK G HL F W ,ac y t o k i n e
profile indicated that interleukin (IL) -12p70, IL-6 and
IL-10 levels were elevated compared to the healthy con-
trols (Figure 4).
Diagnosis
A blood specimen collected on the day of admission was
positive for Lassa NP antigen (Ag) by LFI (Figure 5),
and positive by quantitative NP antigen-capture ELISA,
with a level of 13 μg/mL NP (Figure 6A). Additionally,
IgM levels to recombinant Lassa proteins (NP alone and
NP, GP1, GPC combination) were determined by
ELISA, with low but detectable levels of immunoglobu-
lin to NP and GPC (Figure 6B). IgG levels were not
above background detection upon initial diagnosis (Fig-
ure 6C).
Treatment and hospital course
Intravenous (IV) ribavirin was administered upon LFI
Ag positive diagnosis: a loading dose of 30mg per kilo-
gram followed by 15mg/kg every 6 hours for 4 days and
7.5mg/kg every 8 hours for an additional 6 days. Broad
spectrum antibiotics (ceftriaxone, ciprofloxacin and
metronidazole) and anti-malarials (artemether and qui-
nine) were also started. A single dose of dexamethasone
was given. Five percent and 50% glucose boluses were
given as needed. Upon slight recovery, the patient
requested energy drinks, which were provided (Luco-
zade, a sports-like drink similar to Gatorade in composi-
tion). Despite therapy, G-1180 continued to experience
bleeding abnormalities for the next two weeks including
hematochezia and hemoptysis. Ciprofloxacin was
restarted on the eighth day post onset of illness to treat
a catheter-related infection of his penis, which was
resolved shortly thereafter. The patient required a blood
transfusion on day 8 of illness due to severe anaemia
(Hgb = 7.0 g/dL, Figure 3B). The donor was a Caucasian
American female of the same blood type (A+). A second
blood transfusion was administered on day 21 of illness
( H g b=6 . 5g / d L ,F i g u r e3 B )f r o mat y p eO +C a u c a s i a n
American male donor. On this day the patient was alert,
responsive, able to walk on his own and had stopped
bleeding altogether.
Blood samples were collected daily, except for day 12
of illness. Day 14 post onset of illness was the last day
that diagnostic, metabolic and inflammatory tests were
conducted on patient G-1180. The LFI tests detected
LASV NP in G-1180 through day 8 of illness (Figure 5)
and NP Ag capture ELISA detected LASV NP through
day 11 (Figure 6A; P < 0.05, N = 2). LASV NP antigen
dropped rapidly over 3 days following the onset of riba-
virin treatment (Figure 6A).
Despite the severity of the disease, most of G-1180’s
chemistry levels were near or within the normal range
for a male his age by the end of our monitoring period.
The originally low levels of Na
+,C l
- and TCO2 returned
to normal levels; though, the Alb and TP remained con-
sistently low. The liver function panel decreased signifi-
cantly, although it did not return to within normal
range. BUN and BUN:Cre levels, on the other hand,
returned to normal levels. The analytes that were initi-
ally within the normal range remained stable throughout
the monitoring period except for K
+, which declined.
Cytokine profiles were performed on serum samples
collected daily. G-1180’s IL-12p70, IL-6 and IL-10 levels
were elevated upon admission (day 6) but returned to
normal by day 7. On day 10, a sudden increase in IL-6,
IL-8, IL-10 and tumor necrosis factor (TNF) -alpha
levels was noted. These levels all decreased to back-
ground values the following day. IL-2 was increased on
day 11 only. IL-6 was again elevated on day 13.
Two blood samples have been collected from G-1180
since his discharge from the KGH LFW. A blood sample
for follow-up testing was obtained on day 74 post onset
of illness. At that time, IgM titers against GPC and NP
had risen relative to day 14. Endpoint titers, determined
by NP, GP1, GP2 and Z combination ELISA diagnostics,
revealed a three-fold increase in IgM titer and an eigh-
teen-fold increase in IgG titer from day 6 to 14 post
onset of ilness, and a three-fold increase in both IgM
and IgG titer from day 14 to 74 (additional file 2 table
S1). Additionally, his complete metabolic panel had
returned to the normal range except for a slightly ele-
vated Na
+ a n dT P ,a n dl o wC l
- and Ca
2+.T h el i v e r
function panel had also normalized. A second follow-up
sample obtained on day 108 post onset of illness
revealed slightly elevated Na
+ and K
+,a n dl o wC l
- (data
not shown). The Cre level was below normal and both
ALP and AST were slightly elevated (data not shown).
TP also remained elevated since the previous analysis.
Chemistries of Healthy Volunteers and a Fatal Case of
Lassa Fever
In order to establish the capabilities and reliability of the
Piccolo
®,c o m p l e t ec h e m i s t r i es were performed on
blood drawn from healthy volunteers as well as a single
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Figure 3 A comprehensive metabolic panel was obtained daily by Piccolo analysis. Fourteen metabolic indicators were measured in the serum
of G-1180 daily after admission, through day 14 (with the exception of day 12), using a Piccolo comprehensive metabolic panel disk array (see
additional file 1 figure S1 for Na
+,C l
-,C a
2+,K
+,T C O 2, Alb and TP levels).A Two samples from G-1180 contacts -A and -B were also analyzed, along with
Sierra Leonean and U.S. normal controls. Values were plotted alongside normal ranges for each metabolite, for reference (rose boxes). G-1180
presented with elevated TBil, and extremely high BUN:Cre ratios. Surprisingly, levels of Cre remained within normals levels throughout, in contrastt o
other report cases of Lassa hemorrhagic fever. The most dramatically elevated metabolic indicators were ALP, ALT, and AST, all indicative of severe liver
implication in this case of Lassa fever. Patient G-1177, who succumbed to Lassa fever, presented with elevated TBil, but low BUN:Cre, mainly due to
extremely high Cre levels. This patient also had highly elevated levels of ALP and ALT, but normal levels of AST. Metabolic indicators were assayed in
normal Sierra Leonean and U.S. normals, along with two samples each from G-1180 contacts -A and -B. B Haemoglobin levels (Hb) were measured in
G-1180 on days 8, 12, 19, and 22 post- onset of disease. Low levels of Hb prompted blood transfusions on days 9 and 14.
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Page 6 of 14sample from a patient who succumbed to Lassa Fever.
This last sample (G-1177) was drawn less than 12 hours
prior to expiry.
The chemistries of the three healthy volunteers were
in the normal range as specified by the manufacturer
(Abaxis, Inc.) except for a few values. One subject had a
low serum Na
+, two subjects had low Cl
-, one had a low
TCO2 one had an elevated TP (Figure 3, additional file
1 figure S1).
Subject G-1177 had extremely abnormal labs prior to
expiring. Many of her analytes were above the normal
range specified by Abaxis, Inc., including Na
+,K
+,C l
-,
ALP, ALT, TBil, BUN and Cre (Figure 3, additional file 1
figure S1). Conversely, the TCO2, Alb, BUN:Cre and TP
levels were low. Only the corrected Ca
2+ fell within the
normal range. The AST level was zero. When compared
to healthy volunteers, she presented with high levels of
circulating IL-1beta, IL-12p70, IL-8, IL-6, and IL-10.
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Figure 4 Serum cytokine levels analyzed by multiplex Flow Cytometry. Serum cytokine levels were analyzed with a BenderMed Systems
Human 11-Plex Inflammatory Cytokine kit, and an Accuri C6 Flow Cytometer equipped with dual laser detection. Data was processed and
quantitated with Flow Cytomic Pro software, and plotted on linear scales. G-1180 presented with elevated levels of IL-12p70, IL-6, and IL-10, all
of which decreased by the following day. On day 10 post onset of disease a significant but transient spike in IL-1b, IL-6, IL-8, TNF-a, and IL-10
occurred, that rapidly decreased overnight, mostly to background levels. The only notable cytokine fluctuation in G-1180 contacts occurred in
-A.2 with a dramatic spike in IL-8 that decreased to background levels within 2 days (-A.3). The single point analysis for G-1177 revealed high
levels of IL-1b, IL12p70, IL-6, and IL-10.
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On the night of September 2
nd patient G-1180 was
admitted to the KGH LFW and as routine procedure in
the KGH Lassa fever program, the outreach team was
dispatched to the village of origin to further investigate
the case. Three prior deaths of relatives of G-1180 living
in the same dwelling were reported to the outreach
team at that time. These deaths were attributed to an
undetermined febrile illness and all occurred within the
previous month. The deceased family members included
a 69-year-old woman, a 42-year-old man and a third
individual whose symptoms before death were not
known. The histories of the 2 known individuals are as
follows: On July 9
th the 69-year-old female reportedly
experienced persistent high fever, vomiting, diarrhoea
and severe headaches. A few days after the initial onset
of symptoms the woman travelled to Kenema to seek
medical treatment. The 69-year-old woman was
admitted at the Arab Hospital, Hangha Road, Kenema
for treatment but succumbed on July 16, 2010 without
definitive diagnosis. The body was subsequently trans-
ported to Hangha and buried at the town cemetery (Fig-
ure 1). Two weeks after the death of the 69-year-old
woman, her 42-year-old son living in the same dwelling
as G-1180 fell ill with similar presentations, including
profuse bleeding from all orifices, and succumbed on
August 7, 2010 without visiting a health facility. The 42-
year-old man was buried at Sembehun Town cemetery.
The history of the third, expired relative is unknown.
The outreach team performed a close investigation of
the dwelling, which revealed rodent faeces and holes in
the walls of all rooms, poor food and water storage and
congested home settings. At this time, eight close con-
tacts of G-1180 were identified and blood samples were
collected and transported to KGH LFL for LASV Ag
and IgM analyses. None of the subjects had a recent tra-
velling history outside the township.
Two of the contacts (G-1180-A, female, age 20, and
G-1180-B, female, age 38) tested positive for LASV Ag
and IgM, and were subsequently transported to the
KGH LFW for ribavirin treatment. Despite detecting
LASV Ag and IgM in both patient sera, neither pre-
sented with classical symptoms of the disease. G-1180-A
and -B, provided only three serum samples each during
their 10 day stay in the ward on three consecutive days
starting with date of admission on September 4, 2010.
Patient G-1180-A was admitted with an elevated TP
that declined during ribavirin therapy. Her Alb and Ca
2+
remained low. The daily cytokine profile was unremark-
able when compared to the healthy volunteers except
for a one day increase in IL-8 observed on day two.
Patient G-1180-B developed several abnormalities dur-
ing the 3 day monitoring period. Her TP and TBil
increased drastically; though, her cytokine profile was
unremarkable.
The outreach team conducted sensitization meetings
with the community, including a close door conference
with village heads and health committee members. Gen-
eral education on Lassa fever and preventative measures
were conveyed to the community through a film on the
subject. The team also set rodent traps during their
overnight stay, but Mastomys species, the known rodent
reservoir of Lassa fever virus, were not trapped. The
team was informed that shortly after the onset of G-
1180’s illness, rat poison was applied in the dwelling.
Discussion
The NP is the most abundant polypeptide in Lassa vir-
ions, with approximately 60 molecules per particle.
Thus, detection of NP antigen may be the most sensitive
diagnostic for LASV, particularly in samples presenting
with low antigenemia. Thus LFI and NP Ag detection
ELISA were developed into rapid and confirmatory diag-
nostic platforms, respectively. Additionally, sensitive
assays for the detection of LASV-specific IgM and IgG
(Corgenix Medical Corp.), based on recombinant LASV
protein ELISA, were used to qualitatively measure
immunoglobulin levels (Figure 6B, C). Data from these
sensitive assays suggest that G-1180 was naive to LASV
exposure prior to this incident as he presented with very
low NP-specific IgM levels on day 6, which progressively
increased throughout the monitoring period. Conversely,
GP1 and GP2-specific IgM titers were not statistically
above background levels throughout the same period.
On day 10, low IgG titers were detectable in G-1180 as
^>EϬϭ ϲ ϳ ϴ ϵ ϭϬ ͘ϭ ͘ϯ ͘ϯ ͘ϭ
EŽƌŵĂů 'ϭϭϴϬ 'ϭϭϴϬŽŶƚĂĐƚƐ
ŽŶƚƌŽů>ŝŶĞ
dĞƐƚ>ŝŶĞ
Figure 5 Rapid diagnosis of acute Lassa fever virus infection
by Lateral Flow Immunoassay (LFI) in patient G-1180 and
contacts -A and -B. LFI tests contain a murine monoclonal
antibody capture and an heterologous gold-conjugated antibody
for the detection of LASV nucleoprotein (NP) in the serum of
suspected Lassa fever patients. Twenty-five μL of serum were
applied to the sample well in an LFI module and chased with 3
drops (~ 100 μL) of optimally formulated buffer. After 10 minutes
the results were recorded photographically. A representative normal
serum sample analysis from a Sierra Leonean donor (S.L. N01) is
shown for comparison. Only the control line developed with this
serum sample. Conversely, sera from G-1180 generated a detectable
precipitate in the test line, indicative of LASV NP antigen. The LFI
platform detected NP antigen from days 6 - 8. Days 9 and 10 show
no detectable antigen in this format. Sera from G-1180 contacts -A
and -B did not produce a detectable signal on LFI, despite
detection of antigen by a sensitive NP ELISA (figure 4A).
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contacts, and in two additional patient and contact sera (G-1177 and G-1177-A). An antigen capture ELISA designed with affinity-purified
goat polyclonal antibody reagents was used to detect LASV NP in patient sera (A). LASV NP antigen was not detected in normal sera from Sierra
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of ribavirin administration (quantitative levels indicated), to nearly undetectable levels by day 11. Conversely, antigen levels in G-1180-A and –B
did not drop over the course of three days of ribavirin treatment. G-1180-F registered a significant level of antigen but did not seek treatment.
G-1177 succumbed to acute Lassa fever, with very high levels of viral antigen detected before expiry. LASV-specific IgM (B) [▲, red] and IgG (C)
[●, green] were detected in a recombinant ELISA plate format, coated with NP, GP1, and GP2, or with individually coated proteins. Most Sierra
Leonean sera showed significant levels of IgM, IgG, or both, whereas U.S. normals did not. IgM and IgG levels in G-1180 rose throughout the
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Page 9 of 14determined by endpoint titers, which increased three-
fold through day 14. Immunoglobulins were again mea-
sured on day 74 post onset of illness in G-1180, and
surprisingly IgM titers against glycoprotein and NP had
risen relative to day 14, rather than subsiding (additional
file 2 table S1). An expected increase in IgG titers to
LASV proteins was also observed. Immunoglobulin
levels in G-1180 measured on day 108 post onset of ill-
ness revealed still elevated IgM titers as well as IgG
titers against NP (data not shown). The IgM titer to NP
dropped to approximately one third the qualitative level
measured on day 74, whereas IgG rose slightly com-
pared to the same time point. IgM and IgG levels
against GP1 and GP2 were not significant on days 74
and 108. This phenomenon of persistently high IgM
titers against LASV antigens for weeks, months or
longer, in a significant proportion of convalescent
patients is currently under investigation (Garry et al.,
unpublished data).
The most remarkable aspect of the cytokine profile
obtained at the time of admission was the significant
level of IL-12p70 measured in serum (Figure 4). This
pleitropic proinflammatory cytokine is produced by pha-
gocytic cells, B cells, and other antigen-presenting cells
that modulate adaptive immune responses, promotes
Th1 cell development and is a potent inducer of IFN-g
and other cytokines in peripheral blood T and NK cells.
IFN-g further enhances production of additional IL-12
and other pro-inflammatory cytokines by phagocytic
cells. IL-12 induced IFN-g acts in a positive feedback
loop providing an amplification mechanism in the
inflammatory response [36]. Remarkably on day 7, IL-
12p70 was not detected, but its decrease coincided with
ar i s ei nI F N - g levels, which remained elevated through
day 10, but were undetectable on day 11. Another
increase in IL-12p70 levels was measured on days 11
and 12, the latter coinciding with a second spike in
IFN-g. Though IL-12p70 may have some impact on
pathogenesis of Lassa fever, its role in arenaviral patho-
genesis has not been described. Despite this profile early
in the monitoring period other pro-inflammatory cyto-
kines, such as IL-1b and TNF-a were undetectable, and
IL-6 and IL-8 fluctuated in the lower end of the assay
range. Elevated levels of IL-8 have been previously
reported by Mahanty et al., 2001 to correlate with a
positive outcome in acute Lassa fever infections [37], in
addition to IFN-induced IP-10, which was not measured
in these studies. A very notable albeit short increase in
pro-inflammatory cytokines was measured on day 10,
when IL-6 and IL-8 spiked to very high levels, in addi-
tion to a small spike in IL-1b and TNF-a. The increase
of endogenous pyrogens IL-1b,T N F - a,I L - 6 ,I L - 8o n
day 10 coincided with re-development of a mild fever,
and significantly increased respiratory and pulse rates
(Figure 7). These levels dropped to baseline or were
undetectable 24 hours later. A single spike in IL-2, a
cytokine important in the differentiation and survival of
cytotoxic T cells, and a facilitator of immunoglobulins
by B cells, was measured on day 11.
Concurrent with this observed increase in pro-inflam-
matory cytokines, a significant spike was measured in
the IL-10 levels, an anti-inflammatory cytokine and
potent inhibitor of Th1 cytokines and cellular responses.
This spike coincided with the onset of a significant
increase in the levels of LASV-specific IgM and IgG.
Notably, IL-10 levels were elevated throughout the
seven days of monitoring. Following the spike in pro-
and anti-inflammatory cytokines, body temperature,
respiration and pulse rates on day 10, the patient stabi-
lized. His temperature did not return to febrile levels
again during the course of these studies, and average
respiration and pulse rates stabilized within normal
levels. Thus, it appears that G-1180 experienced a
dynamic interplay of pro- and anti-inflammatory cyto-
kines and their physiological effects were ongoing
throughout the extended analysis period of seven days.
More importantly these results strengthen the hypoth-
esis, as previously proposed by others [35, 37, others],
that an imbalance between pro- and anti-inflammatory
cytokines plays an important role in the development of
Lassa hemorrhagic shock, with poor outcome. Notably,
the marked absence of TNF-a, a potent inducer of
endothelial damage via apoptosis [38] and thrombocyto-
penia [39] throughout the monitored course of illness in
G-1180, with the exception of a spike on day10, suggests
a somewhat regulated and effective immune response at
play. This applies to the marked absence of IL-1b during
the same period. It has been suggested that an early
pro-inflammatory cytokine response followed by down-
regulation to baseline levels, which has been character-
ized in Ebola patients, may also be important in a
regulated and balanced immune response and outcome
in Lassa fever infections [40]. IL-4, a strong mediator of
Th2 CD4+ T cells that stimulate B cells and enhance
the humoral response, and IL-5, which functions as a B
cell stimulator leading to increase in immunoglobulin
secretion were not detected throughout the course of ill-
ness [36].
The two contacts of G-1180 that were admitted to the
KGH LFW presented with lower, albeit significant levels
of LASV NP antigen compared to G-1180 (Figure 6A).
Surprisingly, and despite clear and re-confirmed pre-
sence of NP antigen in the serum of both G-1180-A and
-B contacts by ELISA, levels did not decrease over a two
day period following treatment with ribavirin. Neither
contact presented with or developed classical symptoms
of Lassa fever during their 10-day hospitalization period.
Contact G-1180-A presented with very low but
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Figure 7 Composite analysis of all parameters evaluated for G-1180 in the course of these studies. Data for core temperature, respiration
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Page 11 of 14detectable IgM titer to NP, and background level titers
to GP1 and GP2. G-1180-B presented with significant
IgM titer to GP2, but undetectable titers to GP1 and
NP. In both contacts IgG titers were detectable from the
outset, but remained unchanged throughout the three
days of testing according to endpoint titers. Thus,
potential previous exposure to LASV and development
of protective humoral and/or cellular immunity may
have contributed to the observed Ag positive but asymp-
tomatic status of these two patients
D e s p i t et h ep o o ro u t c o m ef o rp a t i e n tG - 1 1 7 7 ,ap o s i -
tive control used throughout these studies, she pre-
sented with moderate IgM to GP2, low IgM to GP1 and
NP, high IgG to NP, and undetectable IgG to glycopro-
teins. Additionally, G-1177 presented with highly ele-
vated levels of ALP and ALT, but with undetectable
AST. Analysis of cytokines in the single G-1177 sample
revealed similarities with those seen with G-1180. Nota-
bly, elevated levels of IFN-g, IL-12p70, IL-6, IL-8, and
IL-10 were detected. The most remarkable difference
was a highly elevated level of IL-1b in G-1177, which
was only detected in low levels in G-1180 on day 10.
Similar to G-1180’s profile, cytokines IL-2, IL-4, IL-5,
TNF-a, and TGF-b were not detected in G-1177.
Together, this case outlines the severe and prolonged
multi-organ dysregulation, pro- and anti-inflammatory
cytokine up- and down-regulation, and difficulty in
management of acute Lassa fever infections. This case
also delineates the necessity for prompt treatment with
IV ribavirn, fluid management and maintenance of elec-
trolyte balance to counter hypovolemia, hemorrhagic
shock and malnutrition during the early stage of infec-
tion. Given the health status of G-1180 on day 6 post
onset of symptoms, this study points to the possibility
of positive outcomes in Lassa fever patients with
severely compromised metabolic and immunological
presentations.
Conclusions
Lassa fever has a high fatality rate if not diagnosed and
treated promptly. Due to the low economic status of
Lassa endemic areas, it often remains misdiagnosed and
untreated. However, due to advances in diagnostics and
laboratory research equipment at the KGH LFL, strides
are being made towards better understanding the immu-
nological impact of LASV. This case report exemplifies
the utility of these methods in defining the host immune
response to this pathogen. Our results combined with
those of others [35,37-40] that extensively characterized
metabolic and immunological parameters of Lassa fever,
point to a strong divergence in metabolites, cytokines
and immunoglobulin levels in positive versus fatal out-
comes. Further studies on both the cellular immune
response and cytokine profiles early in LASV infections
will be critical in deepening our understanding of Lassa
fever and in closing the gap that currently exists
between the initial time of infection and diagnosis and
treatment.
This case report represents a snapshot of severe Lassa
fever and exemplifies the capabilities of KGH LFL in
diagnosing and monitoring the immunologic response
during and post infection. This report dispels miscon-
ceptions that these studies are impossible in field hospi-
tal settings and demonstrates the potential to deploy
diagnostic capabilities that will drastically impact treat-
ment of Lassa fever by allowing the rapid identification,
isolation and treatment of Lassa fever cases. Lastly the
data in this manuscript provides insights into the clini-
cal course of Lassa fever. Not only will these data
inform clinical case management but they will also be
critical to validating animal models currently being uti-
lized for testing new candidate therapeutics and
vaccines.
Additional material
Additional File 1: Figure S1 - A comprehensive metabolic panel was
obtained daily by Piccolo analysis. Fourteen metabolic indicators were
measured in the serum of G-1180 daily after admission, through day 14
(with the exception of day 12), using a Piccolo comprehensive metabolic
panel disk array (see Figure 3A for ALP, ALT, AST, BUN, TBil, Cre). G-1180
presented with low serum Na
+,C l
-, and Ca
2+ions, with K
+, acidotic (low
TCO2) and low Alb and TP levels. Contrastingly, G-1177 presented with
high Na
+,C l
-,K
+, low Ca
2+, and normal TCO2. Metabolic indicators were
assayed in normal Sierra Leonean and U.S. normals, along with two
samples each from G-1180 contacts -A and -B.
Additional File 2: Table S1 - Determination of LASV Ag specific
immunoglobulin M and G endpoint titers with NP, GP1, GP2 and Z
combination ELISA. IgM and IgG endpoint titers were determined for
G-1180 and his contacts (A-L). G-1180 was admitted to KGH LFW with
relatively low IgM and IgG titers that increased during hospitalization and
upon convalescence. Contacts G-1180-A and -B presented to KGH LFW
with significant IgM and IgG titers, suggesting previous exposure to
LASV, and remained asymptomatic throughout the hospitalization
timeline. Additionally, G-1180-C through -L displayed IgM, IgG, or dual
immunoglobulin titers.
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